Next Generation Sequencing (NGS) kits

Award value estimated based on previous spend for 2023-24 financial year.

This is a direct award to the existing supplier to save a significant amount of rework that would be required if the genetics lab was to switch to an alternative supplier.

This will cover the spend for 2024-25 financial year.

It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with primary immune deficiencies and bone marrow failure and correct patient management to prevent irreversible brain damage in metabolic conditions.